Effect of Modified Erchentang on PPARγ Expression in Lung Tissue of Rats with Chronic Obstructive Pulmonary Disease
10.13422/j.cnki.syfjx.20191501
- VernacularTitle: 二陈汤加味对慢性阻塞性肺疾病大鼠模型肺组织PPARγ信号通路的影响
- Author:
Wen-ying XIE
1
;
Yong-sheng BAO
1
;
Jun-yue WANG
1
;
Li-zhi SHANG
1
;
Ke WU
1
;
Liang-zhi ZHANG
1
;
Liang LI
1
;
Xiao-yan WANG
1
;
Qian-hong SONG
1
Author Information
1. Henan University of Chinese Medicine, Zhengzhou 450046, China
- Publication Type:Research Article
- Keywords:
modified Erchentang;
chronic obstructive pulmonary disease;
peroxisome proliferator-activated receptor gamma(PPARγ);
interleukin-6(IL-6);
IL-10;
tumor necrosis factor-α(TNF-α)
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(23):26-33
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the effect of modified Erchentang on peroxisome proliferator-activated receptor gamma (PPARγ) protein and gene expressions in lung tissue of chronic obstructive pulmonary disease (COPD) rat model, and the expressions of interleukin-6 (IL-6), interleukin-10 (IL-10) and tumor necrosis factor-alpha (TNF-α) in serum, lung homogenate and bronchoalveolar lavage fluid. Method: Seventy SD rats were randomly divided into seven groups:normal group, model group, high, medium and low-dose modified Erchentang groups (40, 20, 10 g · kg-1 · d-1), Xiaokechuan group (5 g · kg-1 · d-1), and Erchentang group (5 g · kg-1 · d-1). The rat COPD model was established through smoking and intratracheal instillation of lipopolysaccharide (LPS). After successful modeling, the treatment group was given drug by gavage, while the normal group and the model group were given the same amount of saline. The concentrations of IL-6, IL-10 and TNF-α in serum, lung homogenate and bronchoalveolar lavage fluid(BALF) of rats were measured by enzyme-linked immunosorbent assay (ELISA). Real-time fluorescence quantitative PCR (Real-time PCR) was used to detect the expression of peroxisome proliferator-activated receptor gamma (PPARγ), and immunohistochemistry (IHC) and Western blot were used to detect the expression of PPARγ in lung tissue. Result: Compared with the normal group, the levels of IL-6 and TNF-α in serum, lung homogenate and BALF of the model group rats increased significantly (P<0.01), while IL-10 decreased significantly (P<0.01). The expressions of PPARγ mRNA in lung tissue of rats in model group were significantly decreased (P<0.01), and the expression of PPARγ protein was significantly inhibited(P<0.01). Compared with the model group, the levels of IL-6 and TNF-α in serum, lung homogenate and BALF of each treatment group decreased to varying degrees(P<0.01), while IL-10 increased to varying degrees. The excitation of IL-10 and the inhibition of IL-6 and TNF-α in the middle-dose Erchentang group were particularly significant. The PPARγ mRNA and protein expressions in lung tissue of rats in each treatment group were increased to varying degrees (P<0.01). Conclusion: Modified Erchentang may improve pulmonary inflammation and pulmonary function in COPD rats by increasing the expression of PPARγ and the content of IL-10 and decreasing the contents of IL-6 and TNF-α.
